AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Soleo Health Among First to Offer HEMA Biologics’™ SEVENFACT®, a Newly Released Treatment for Bleeding Disorders

December 21, 2020 GMT

FRISCO, Texas--(BUSINESS WIRE)--Dec 21, 2020--

Soleo Health, an innovative leader and national provider of complex specialty pharmacy and infusion services, announced today it is now offering SEVENFACT, a newly released drug by HEMA Biologics TM for the treatment and control of bleeding disorders in adolescent and adult patients with Hemophilia A or B with inhibitors.

ADVERTISEMENT

SEVENFACT, approved by the U.S. Food and Drug Administration in April 2020, was made available to the marketplace on December 10 th, 2020. Soleo Health is among the first to offer the drug to patients, providers and payors.

SEVENFACT is designed to bypass the presence of an inhibitor that some patients produce against the clotting factor concentrates they have used as a treatment, thereby helping to treat their bleeding disorders. Several options have been made available for bleeding disorders in recent years, yet there were no new treatments for inhibitor-related bleeding.

“Soleo Health is on the cutting edge in terms of forging manufacturer relationships and bringing the latest in clinical advancements to our patients and prescribing physicians. We continue to enhance and expand our portfolio by including new pharmaceutical treatments. We care for hundreds of patients annually with hemophilia and bleeding disorders, including those affected by an inhibitor. SEVENFACT affords the Company an opportunity to offer additional treatment to help better serve our bleeding disorders population, an area where we have garnered significant expertise, and to offer yet another beneficial treatment,” said Craig Vollmer, chief commercial officer at Soleo Health.

“Patients and families impacted by inhibitors have limited options available for the treatment and control of bleeding. As inhibitor patients continue to suffer the consequences of bleeding, bypassing agents will remain an essential part of disease management,” explains Dr. Allan Alexander, vice president of medical affairs at HEMA Biologics. “We are pleased to bring SEVENFACT, a treatment that provides a proven hemostatic benefit in the setting of inhibitor-related bleeding along with demonstrated bleed resolution using a single dose.”

ADVERTISEMENT

About Soleo Health

Frisco, Texas-based Soleo Health is an innovative national provider of complex specialty pharmacy and infusion services, administered in the home or at alternate sites of care.

Soleo Health’s interdisciplinary team, comprised of experienced clinical pharmacists and registered nurses, utilizes a consistent patient management process, which leads to quantifiable clinical and economic value while improving the patient experience.

Soleo Health operates 20 locations throughout the U.S. with national nursing coverage and pharmacy licensure in 50 states and is accredited by The Joint Commission. For more information, visit www.soleohealth.com or connect with Soleo Health on LinkedIn, Facebook and Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20201221005010/en/

Susan Turkell, 303-766-4343,sturkell@pairelations.com 

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: TECHNOLOGY PHARMACEUTICAL ONCOLOGY OTHER SCIENCE RESEARCH MEDICAL DEVICES INFECTIOUS DISEASES HOSPITALS INSURANCE CLINICAL TRIALS CARDIOLOGY BIOTECHNOLOGY PROFESSIONAL SERVICES HEALTH PRACTICE MANAGEMENT MANAGED CARE SCIENCE NURSING MEDICAL SUPPLIES SOFTWARE FDA DIABETES OTHER HEALTH

SOURCE: Soleo Health

Copyright Business Wire 2020.

PUB: 12/21/2020 08:00 AM/DISC: 12/21/2020 08:00 AM

http://www.businesswire.com/news/home/20201221005010/en